• Home Blog Tag Dystrophic epidermolysis bullosa market

dystrophic epidermolysis bullosa market

May 06, 2025

Abeona Secures FDA Nod for ZEVASKYN, the First Gene Therapy for RDEB; AbbVie Gains FDA Approval for RINVOQ in Giant Cell Arteritis; Lantern Pharma Advances LP-184 with IND Clearance for TNBC Trial; Ichnos Glenmark Earns FDA Fast Track for ISB 2001 in Multiple Myeloma; Rezolute Wins Breakthrough Therapy Designation for Ersodetug in Tumor-Induced Hypoglycemia

gene-therapies-for-epidermolysis-bullosa-treatment

Mar 25, 2024

Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology

Gene Therapies for Dystrophic Epidermolysis Bullosa

Jun 16, 2023

Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

dystrophic-epidermolysis-bullosa-treatment-market

Aug 08, 2022

Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epidermolysis Bullosa Treatment Market?

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper